Andrea Cruz

Andrea Cruz serves as a Staff Researcher in the Nanodevices Group at the International Iberian Nanotechnology Laboratory (INL) and leads the nanomedicine/molecular medicine area at Prochild CoLAB Association since 2020. Her work centers on developing advanced biosensor technologies for clinical diagnostics and biomarker validation.

Her academic foundation includes:

• Master in Science from Montfort University, UK
• PhD in Health Sciences from the University of Minho, Portugal

Postdoctoral training was completed at Portugal's Life and Health Sciences Research Institute, the Trudeau Institute (USA), and Instituto de Biologia Molecular e Celular (IBMC)/i3S, focusing on immune biomarker identification and nanotechnology applications.

Research interests emphasize nanotechnology-driven diagnostic solutions, particularly electrochemical biosensors for multiplex biomarker detection in mental health, oncology, and inflammatory diseases. Her methodology integrates clinical validation protocols with point-of-care device development for non-invasive sample analysis.

Publication trends reveal consistent innovation in translating nanotechnology to clinical diagnostics, with recent work targeting pediatric mental health through salivary biomarkers, colorectal cancer screening via fecal biomarkers, and neurodegenerative disease diagnostics using novel biosensing platforms.

Scientific recognition includes:

• Excellence Award Pulido Valente
• Best SPI Paper Award
• Excellence Award Mário Arala Chaves

She actively supervises graduate students and contributes to European and National research projects, advancing nanomedicine applications while developing clinical validation frameworks for diagnostic technologies.

Current laboratory leadership spans INL's Nanodevices Group and Prochild CoLAB Association, where her team pioneers nanotechnology solutions for children's health diagnostics and molecular medicine applications.